KR950703999A - 변성된 인슐린-유사 성장인자(modified insulin-like growth factors) - Google Patents
변성된 인슐린-유사 성장인자(modified insulin-like growth factors)Info
- Publication number
- KR950703999A KR950703999A KR1019950702108A KR19950702108A KR950703999A KR 950703999 A KR950703999 A KR 950703999A KR 1019950702108 A KR1019950702108 A KR 1019950702108A KR 19950702108 A KR19950702108 A KR 19950702108A KR 950703999 A KR950703999 A KR 950703999A
- Authority
- KR
- South Korea
- Prior art keywords
- igf
- peg
- mutein
- polyethylene glycol
- conjugate
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract 15
- 102000013275 Somatomedins Human genes 0.000 title abstract 7
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 26
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 25
- 150000001413 amino acids Chemical group 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 8
- 235000018417 cysteine Nutrition 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 12
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- -1 polyethylene Polymers 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 3
- 210000004897 n-terminal region Anatomy 0.000 claims 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 2
- 239000004698 Polyethylene Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229920000573 polyethylene Polymers 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98051992A | 1992-11-25 | 1992-11-25 | |
| US07/980,519 | 1992-11-25 | ||
| PCT/US1993/011458 WO1994012219A2 (fr) | 1992-11-25 | 1993-11-24 | Facteur de croissance insulinoide modifie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950703999A true KR950703999A (ko) | 1995-11-17 |
Family
ID=25527621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950702108A KR950703999A (ko) | 1992-11-25 | 1993-11-24 | 변성된 인슐린-유사 성장인자(modified insulin-like growth factors) |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0679095A1 (fr) |
| JP (1) | JPH08506095A (fr) |
| KR (1) | KR950703999A (fr) |
| AU (1) | AU6048294A (fr) |
| CA (1) | CA2149048A1 (fr) |
| WO (1) | WO1994012219A2 (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| AU2601895A (en) * | 1994-05-24 | 1995-12-18 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| WO1998037200A2 (fr) | 1997-02-21 | 1998-08-27 | Genentech, Inc. | Conjugues de polymeres et de fragments d'anticorps et anticorps monoclonaux humanises anti-il-8 |
| US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
| US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
| US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
| US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
| EP1067959A2 (fr) | 1998-04-03 | 2001-01-17 | Chiron Corporation | Utilisation d'igf1 pour traiter des maladies du cartilage articulaire |
| KR100731826B1 (ko) * | 1999-01-14 | 2007-06-22 | 볼더 바이오테크놀로지 인코퍼레이티드 | 유리 시스테인 잔기를 함유하는 단백질의 제조 방법 |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| EP1172372B1 (fr) | 1999-04-02 | 2005-08-31 | Ajinomoto Co., Inc. | Procede de production de sous-unite de peptide issue d'une proteine de polymere |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| IL152804A0 (en) * | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| JP2005508162A (ja) | 2001-10-02 | 2005-03-31 | ジェネンテック・インコーポレーテッド | Ａｐｏ−２リガンド変異体とその使用法 |
| US20060141561A1 (en) | 2002-06-24 | 2006-06-29 | Kelley Robert F | Apo-2 ligand/trail variants and uses thereof |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| EP1674113A1 (fr) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
| ES2553160T3 (es) * | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| WO2007041614A2 (fr) | 2005-10-03 | 2007-04-12 | Bolder Biotechnology, Inc. | Inhibiteurs de vegf a action prolongee et leurs methodes d'utilisation |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| BRPI0715754A2 (pt) | 2006-08-31 | 2013-07-09 | Hoffmann La Roche | mÉtodo para a produÇço de fator do crescimento similar Á insulina i |
| EP2091968A2 (fr) | 2006-10-26 | 2009-08-26 | Novo Nordisk A/S | Variantes il-21 |
| EP2102355B1 (fr) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Protéines et peptides à action prolongée et procédés de production et d'utilisation de ces derniers |
| BR112012019992A2 (pt) * | 2010-02-11 | 2020-08-18 | F. Hoffmann-La Roche Ag. | conjugados de igf-i poli (etileno glicol) |
| KR20160042438A (ko) | 2013-08-12 | 2016-04-19 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
| TW201623337A (zh) | 2014-05-01 | 2016-07-01 | 建南德克公司 | 抗－因子ｄ抗體變異體及其用途 |
| EP3368090A1 (fr) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Conjugués de variants d'anticorps anti-facteur d et leurs utilisations |
| WO2017075173A2 (fr) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anticorps et conjugués anti-facteur d |
| CN115867649A (zh) | 2020-03-24 | 2023-03-28 | 基因泰克公司 | Tie2结合剂及其使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| DE69128944T2 (de) * | 1990-05-04 | 1998-06-25 | American Cyanamid Co | Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten |
-
1993
- 1993-11-24 AU AU60482/94A patent/AU6048294A/en not_active Abandoned
- 1993-11-24 JP JP6513381A patent/JPH08506095A/ja active Pending
- 1993-11-24 WO PCT/US1993/011458 patent/WO1994012219A2/fr not_active Application Discontinuation
- 1993-11-24 CA CA002149048A patent/CA2149048A1/fr not_active Abandoned
- 1993-11-24 EP EP94907044A patent/EP0679095A1/fr not_active Withdrawn
- 1993-11-24 KR KR1019950702108A patent/KR950703999A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994012219A3 (fr) | 1994-07-21 |
| EP0679095A1 (fr) | 1995-11-02 |
| CA2149048A1 (fr) | 1994-06-09 |
| AU6048294A (en) | 1994-06-22 |
| WO1994012219A2 (fr) | 1994-06-09 |
| JPH08506095A (ja) | 1996-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950703999A (ko) | 변성된 인슐린-유사 성장인자(modified insulin-like growth factors) | |
| Rothe et al. | Growth factors: their biology and promise in dermatologic diseases and tissue repair | |
| KR970706842A (ko) | 아실화된 인슐린 동족체(Acylated Insulin Analogs) | |
| US3917824A (en) | Pharmaceutical compositions containing epidermal growth factor or closely related derivatives thereof for inhibiting the secretion of acidic gastric juice in warm blooded animals | |
| US5747446A (en) | Modified polypeptides with increased biological activity | |
| JPH02504279A (ja) | インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド | |
| DE69631329T2 (de) | Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol | |
| ES2163444T3 (es) | Composiciones y metodos para la administracion oral de farmacos. | |
| KR890003400A (ko) | 경비(經鼻)투여용 생리 활성 펩티드 분말 조성물(제제) | |
| WO1990000397A1 (fr) | Composition pharmaceutique pour interleukine-2 contenant des stabilisants physiologiquement compatibles | |
| FI874706A0 (fi) | Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi | |
| RU94033520A (ru) | Впрыскиваемый лецитиновый гель | |
| KR910001044A (ko) | 안정화된 fgf 조성물 및 그의제조 | |
| KR880000463A (ko) | 사슬 결합법 | |
| CA2365742A1 (fr) | Formulations de peptides agonistes d'amyline | |
| KR20020010920A (ko) | 각질세포 성장 인자-2 제제 | |
| LU90025I2 (fr) | Reteplase et ses dérivés pharmaceutiquement acceptables (Rapilysin R) | |
| JP3829991B2 (ja) | Ｈｇｈ含有医薬組成物 | |
| RU97105374A (ru) | Модифицированные белки | |
| KR900003205A (ko) | 제약 화합물 | |
| KR20100099298A (ko) | Ｐｅｇ인터페론베타 제형 | |
| CA2311648A1 (fr) | Complexe ifnar2/ifn | |
| BRPI0808259A2 (pt) | "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada" | |
| DE69837997D1 (de) | Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels | |
| FI893833A0 (fi) | Rekombinant aktivator foer naturliga doedarceller. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |